We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
-0.77%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$7.55B
AUM Growth
-$472M
(-5.9%)
Cap. Flow
-$301M
Cap. Flow
% of AUM
-3.99%
Top 10 Holdings %
Top 10 Hldgs %
20.77%
Holding
863
New
59
Increased
344
Reduced
256
Closed
128
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nike
NKE
|
+$25.4M |
| 2 |
AbbVie
ABBV
|
+$21.9M |
| 3 |
KYNB
Kyntra Bio
KYNB
|
+$19.2M |
| 4 |
Waste Management
WM
|
+$19M |
| 5 |
Gilead Sciences
GILD
|
+$17.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$70.2M |
| 2 |
ARRY
Array Biopharma Inc
ARRY
|
+$45.8M |
| 3 |
Biogen
BIIB
|
+$43.3M |
| 4 |
Meta Platforms (Facebook)
META
|
+$24.8M |
| 5 |
Amgen
AMGN
|
+$21.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 31.81% |
| 2 | Technology | 18.27% |
| 3 | Financials | 10.05% |
| 4 | Consumer Discretionary | 9.39% |
| 5 | Communication Services | 7.66% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
551
Artivion
AORT
$1.27B
| $1.22M | 0.02% |
45,000
| – | – |
|
552
MSCI
MSCI
$41.5B
| $1.22M | 0.02% |
5,595
-444
| -7% | -$103K |
|
553
Canadian Natural Resources
CNQ
$93.4B
| $1.22M | 0.02% |
93,154
-40,589
| -30% | -$503K |
|
554
Extra Space Storage
EXR
$31.3B
| $1.19M | 0.02% |
10,221
-656
| -6% | -$75.9K |
|
|
STML
555
DELISTED
Stemline Therapeutics, Inc.
STML
| $1.19M | 0.02% |
114,000
+34,000
| +43% | +$445K |
|
556
Canadian Pacific Kansas City
CP
$81.1B
| $1.18M | 0.02% |
26,515
+630
| +2% | +$29.6K |
|
557
Akebia Therapeutics
AKBA
$343M
| $1.18M | 0.02% |
300,000
| – | – |
|
558
APA Corp
APA
$12.3B
| $1.17M | 0.02% |
45,641
-2,797
| -6% | -$67.1K |
|
|
AMTD
559
DELISTED
TD Ameritrade Holding Corp
AMTD
| $1.17M | 0.02% |
25,020
+4,030
| +19% | +$193K |
|
|
EPZM
560
DELISTED
Epizyme, Inc
EPZM
| $1.15M | 0.02% |
+111,500
| New | +$1.41M |
|
561
Advanced Drainage Systems
WMS
$11B
| $1.15M | 0.02% |
35,570
+8,918
| +33% | +$290K |
|
562
TransUnion
TRU
$14.9B
| $1.14M | 0.02% |
14,099
-1,149
| -8% | -$92.4K |
|
|
NBL
563
DELISTED
Noble Energy, Inc.
NBL
| $1.14M | 0.02% |
50,854
-48,193
| -49% | -$1.07M |
|
564
CarMax
KMX
$8.29B
| $1.13M | 0.02% |
12,851
+1,025
| +9% | +$88K |
|
565
Regency Centers
REG
$15.1B
| $1.13M | 0.02% |
16,270
-2,104
| -11% | -$140K |
|
|
AUY
566
DELISTED
Yamana Gold, Inc.
AUY
| – | – |
-316,346
| Closed | -$1.01M |
|
567
NVR
NVR
$16.9B
| $1.11M | 0.01% |
299
-113
| -27% | -$398K |
|
568
Western Union
WU
$2.55B
| $1.1M | 0.01% |
47,625
-7,369
| -13% | -$159K |
|
|
ABMD
569
DELISTED
Abiomed Inc
ABMD
| $1.08M | 0.01% |
6,082
+1,661
| +38% | +$359K |
|
|
DISCK
570
DELISTED
Discovery, Inc. Series C Common Stock
DISCK
| $1.08M | 0.01% |
43,928
-192,295
| -81% | -$5.2M |
|
571
Copart
CPRT
$27.6B
| $1.06M | 0.01% |
52,940
-10,712
| -17% | -$208K |
|
572
Synopsys
SNPS
$74.5B
| $1.06M | 0.01% |
7,737
+581
| +8% | +$78.6K |
|
573
Bunge Global
BG
$22.8B
| $1.05M | 0.01% |
18,568
+3,490
| +23% | +$195K |
|
574
Fidelity National Financial
FNF
$14B
| $1.05M | 0.01% |
24,507
| – | – |
|
575
Targa Resources
TRGP
$57.4B
| $1.04M | 0.01% |
25,949
| – | – |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q3 2019 Portfolio in Review
As of Q3 2019, Candriam SCA held 863 positions worth $7.55B, down 5.9% from $8.02B the previous quarter. Its ten largest holdings account for 21% of the portfolio.
Candriam SCA withdrew a net $301M in Q3 2019, closing 128 positions and reducing 256 holdings. Its most notable exit was Celgene Corp, an estimated $70.2M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 32% of assets, down from 33% a quarter earlier, followed by Technology and Financials.
Against the trend, Candriam SCA opened a new position in Nike worth $27.8M.
- Candriam SCA's largest Q3 2019 buy was Nike: 295,763 shares worth $27.8M.
- Candriam SCA added most to AbbVie in Q3 2019, an estimated $21.9M increase.
- Candriam SCA's biggest Q3 2019 reduction was Biogen, cutting an estimated $43.3M.
- Candriam SCA fully exited Celgene Corp in Q3 2019, selling an estimated $70.2M.
- Candriam SCA's ten largest holdings make up 21% of its $7.55B portfolio in Q3 2019.
- Candriam SCA opened 59 new positions and closed 128 in Q3 2019.
- Candriam SCA's portfolio value fell 5.9% quarter-over-quarter to $7.55B.
Based on Candriam SCA's 13F filing for Q3 2019, filed 21 Oct 2019.